A phase 1b/2 trial (NCT04874194) revealed that the combination treatment of omacetaxine and venetoclax (Venclexta) in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with RUNX1 mutation showed…
Omacetaxine and Venetoclax Show Benefits in MDS, No Improvement in AML | Targeted Oncology
